Clovis Oncology, Inc. (CLVS) Shares Down 5.7% on Insider Selling

Jay Anderson
July 16, 2017

1 is equivalent to a buy rating, 3 a hold rating, and 5 a sell rating. Therefore 0 are positive. Iron Mountain Incorporated had 3 analyst reports since October 9, 2015 according to SRatingsIntel. The stock of Ross Stores, Inc. Bernstein maintained the shares of ROST in report on Wednesday, March 2 with "Market Perform" rating. They now have a United States dollars 125 price target on the stock. Chardan Capital Markets downgraded it to "Sell" rating and $36 target in Friday, February 3 report. 28,425 were reported by Wells Fargo & Mn. Goldman Sachs Group, Inc. The rating was maintained by UBS on Tuesday, November 3 with "Sell". A number of brokerages have recently issued reports on CLVS. Endurant Capital Management Lp acquired 10,100 shares as Clovis Oncology Inc (CLVS)'s stock declined 20.61%. FMR LLC now owns 1,816,859 shares of the biopharmaceutical company's stock valued at $115,679,000 after buying an additional 1,327,703 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. increased its position in Clovis Oncology by 20.0% in the fourth quarter. Based on the recent close, the shares have dropped -4.29% over the past five trading days. About 1.05M shares traded.

Clovis Oncology, Inc., launched on April 20, 2009, is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other global markets. It has outperformed by 266.01% the S&P500. Blackrock Fund Advsrs stated it has 907,781 shares or 0% of all its holdings. The insider now directly owns 209,583 shares worth $19,384,332. Charles Riv Labs Intl Inc (NYSE:CRL) was reduced too.

Investors sentiment decreased to 1 in 2016 Q4. Its down 0.97, from 2 in 2016Q3. It is positive, as 13 investors sold ZAGG shares while 34 reduced holdings. 38 funds opened positions while 42 raised stakes. Bankshares Of Mellon owns 0% invested in Clovis Oncology Inc (NASDAQ:CLVS) for 174,282 shares. Ngam L P holds 57,232 shares or 0.08% of its portfolio. National Bank Of Ny Mellon Corp holds 158,794 shares or 0% of its portfolio.

Archon Capital Management Llc decreased Staar Surgical Co (STAA) stake by 53.14% reported in 2016Q4 SEC filing. Moreover, Tiaa Cref Inv Mngmt Ltd Company has 0.01% invested in Clovis Oncology Inc (NASDAQ:CLVS). Northern Tru Corp reported 459,463 shares. Susquehanna Intll Grp Incorporated Ltd Liability Partnership holds 0% or 103,678 shares in its portfolio. Leerink Swann also issued estimates for Clovis Oncology's Q3 2017 earnings at ($1.21) EPS, Q4 2017 earnings at ($1.12) EPS, FY2017 earnings at ($4.95) EPS, FY2018 earnings at ($3.79) EPS, FY2019 earnings at ($2.17) EPS, FY2020 earnings at $0.16 EPS and FY2021 earnings at $3.16 EPS. Also, the equity price jumped 72.11% % in three months, taking the six-month increase to 87.49% as of recent close. Moreover, Aqr Capital Management Ltd Liability has 0.01% invested in Zagg Inc (NASDAQ:ZAGG). Deutsche Financial Bank Ag owns 126,195 shares for 0% of their portfolio. Td Asset Mngmt invested 0% of its portfolio in Clovis Oncology Inc (NASDAQ:CLVS).

Since March 15, 2017, it had 0 insider buys, and 3 selling transactions for $528,600 activity.

Specifically, insider Gillian C. Ivers-Read sold 3,000 shares of the stock in a transaction dated Thursday, June 15th. ValuEngine raised shares of Clovis Oncology from a sell rating to a hold rating in a research note on Friday, June 2nd. Therefore 76% are positive. Five analysts have issued estimates for Clovis Oncology's earnings, with estimates ranging from $11.50 million to $17.50 million. The firm has "Neutral" rating given on Tuesday, December 20 by Chardan Capital Markets.

Mourinho: United need two more signings
I've played with a few lads at club level and worldwide level and there is also some young lads. It is obvious, it is public and we have not reached an economic agreement.

03/14/2017 - Clovis Oncology, Inc. had its " rating reiterated by analysts at Piper Jaffray. The company was maintained on Monday, January 23 by Stifel Nicolaus.

CLVS has been the subject of several other reports. The rating was maintained by WallachBeth Capital with "Buy" on Thursday, September 10. The stock has "Neutral" rating by Mizuho on Wednesday, August 24. The firm has "Hold" rating by Benchmark given on Friday, January 29.

Traders are a little more bearish on shares of Clovis Oncology, Inc. of late looking at the increase in short interest. The stock was trading on above-average volume. About 46,422 shares traded. Zagg Inc (NASDAQ:ZAGG) has risen 54.72% since July 14, 2016 and is uptrending. It has underperformed by 16.70% the S&P500.

Ross Stores, Inc. and its subsidiaries operate two brands of off-price retail apparel and home fashion stores-Ross Dress for Less and dd's DISCOUNTS. The stock's market capitalization is 4.10B, it has a 52-week low of 13.43 and a 52-week high of 96.92. It has a 25.85 P/E ratio.

Clovis Oncology, Inc. has a 50 day moving average of 64.85 and a 200 day moving average of 58.78. 39 funds opened positions while 136 raised stakes. 341.62 million shares or 0.09% more from 341.30 million shares in 2016Q3 were reported. Voloridge Invest Llc holds 183,693 shares or 0.18% of its portfolio. Alliancebernstein Lp reported 0.01% stake. Twin Capital Management has 57,928 shares. Millennium Mgmt Limited Liability Company, a New York-based fund reported 1.08M shares. 646 are held by Benjamin F Edwards. (NASDAQ:ROST) for 147,783 shares. Pictet Asset Mngmt Ltd holds 0.03% or 195,285 shares in its portfolio. 155,612 were accumulated by Proshare Limited Company. Citigroup has 247,642 shares for 0.01% of their portfolio. Montag Caldwell Ltd Liability Com holds 0.02% or 12,013 shares in its portfolio. Da Davidson Communications has invested 0.04% in Clorox Co (NYSE:CLX).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Other reports by BadHub

Discuss This Article

FOLLOW OUR NEWSPAPER